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In The Netherlands about 1650 women are treated for
cervical cancer every year and 350 of them die of the disease
(Central Bureau voor de Statistiek, 1984). Carcinoma of the
cervix is the second most frequent tumour in women under
40.
For patients with stage IB and IIA the primary treatment
is surgery and for stages IIB, III and IV it is radiotherapy.
The 5 year survival rate in IB and IIA patients is 85%.
However, the clinical staging is not always correct (Nagell
et al., 1971). Pelvic lymph node metastases are found in
18-24% of these patients and 15-20% have tumour spread
into the parametria (Ketting, 1981; Bleker et al., 1983). In
these cases additional radiotherapy is given, which means that
the patients are then subjected to the risk of complications
from both therapies. The size of the tumour and the depth
of infiltration are important prognostic factors, but it is
impossible to estimate them accurately pre-operatively
(Burghardt et al., 1977). For these reasons a reliable tumour
marker for cervical cancer would greatly improve its
diagnosis, staging and treatment.
Kato et al. (1977) published results on the development of
a radioimmunoassay (RIA) based on a polyclonal antiserum.
A purified homogenate of cervical cancer tissue called Ta-4,
was used as antigen. They found that the presence of
squamous carcinoma of the cervix corresponded to elevated
serum levels of Ta-4.
This study reports the Ta-4 levels in patients with
squamous cervical cancer treated in the Netherlands Cancer
Institute, and their relation to the clinical stage of the
disease.
Ta-4 levels were measured in serum collected before the
start of primary treatment from 66 patients, who were
treated between January 1981 and May 1985 in the Antoni
van Leeuwenhoek Hospital of the Netherlands Cancer
Institute. We sought 10-20 patients per stage but this was
not achieved in stage IV, because of the low incidence. To
determine the normal distribution, Ta-4 was also measured
in serum of 50 healthy women. Ninety-five percent of them
had a Ta-4 level below 2.7 ngml-1, so this was taken as the
upper normal value. Clinical data were collected retro-
spectively from medical files. All patients were clinically
staged according to FIGO. The histological grade of the
tumour was described as good, moderate or poorly dif-
ferentiated, according to established criteria. Haemoglobin
(Hb), hematocrit (Ht) and white blood count (WBC) were
measured with a Coulter S4-plus (Coulter Electronics,
Luton, Bedfordshire, UK) and creatinine, gamma glutamyl
transpeptidase (y-GT) and alkaline phosphatase (APh) with
Eppendorf's automatic analyser (Eppendorf, Epos,
Hamburg, West Germany). The amount of Ta-4 in serum
was measured with the aid of an Abbott SCC RIA kit
(Dianabot Co. Ltd., Tokyo, Japan). The age of the patients
varied from 30 to 79 with a mean of 57. Fifteen of them
were in stage IB, 18 in stage IIA, 16 in IIB, 12 in III and 5
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in stage IV. Patients with stage IB or IIA were treated with
radical surgery, followed by radiotherapy in cases of positive
pelvic lymph nodes (5 patients) or tumour spread into the
parametria (1 patient). Patients with stage IIB, III or IV
received radiotherapy in a dose of 40Gy externally to the
pelvis and 16Gy by brachytherapy.
All patients were followed to date or until death. Two
patients were lost to follow up, one on account of
emigration, the other because she refused further treatment.
A recurrence was seen in 28 patients and 17 died of the
disease 1 to 33 months after the start of treatment. We
correlated Ta-4 with age, stage, histological tumour differen-
tiation, laboratory assays (Hb, Ht, WBC, APh, y-GT,
creatinine) and clinical status. For statistical analysis the
t-test, analysis of variance and Student Newman Keuls test
were used (Keuls, 1952). The Ta-4 level was above the
normal value of 2.7ngml-' in 53% of patients. When the
clinical stage was taken into account it was found that the
percentage of patients with values >2.7 ngml - increased
from 26.6% in stage IB to 100% in stage IV (see Table I).
Figure 1 shows the Ta-4 levels per stage. The mean Ta-4
level in stage IB (2.3ngml-1) differs significantly from the
mean level in stage IIA (4.09ngml-') (P=0.03), and stage
IIA differs significantly from the mean level in stage IIB
(16.Ongml-1) (P=0.03). Ta-4 levels in stage IIB, III and IV
are not significantly different. No correlation was found
between Ta-4 and age, laboratory assays (Hb, WBC, APh,
y-GT and creatinine) or histological grade of the tumour.
Since we were interested in the impact of positive lymph
nodes on the Ta-4 level, we compared Ta-4 levels in patients
with stage IB or IIA with or without lymph node metastasis.
After logarithmic transformation because of normal
distribution a significant difference was found. Since only
one patient in stage IIA had tumour spread into the
parametria, comparison with the other groups was
impossible. Patients with a recurrence (follow up of 2 years
or more) had a significantly higher mean log Ta-4 value at
the time of the initial diagnosis than those without
recurrence (0.79 vs. 0.49) (P=0.02). However when sub-
divided into groups A (stage IB and IIA), B (stage IIB) and
C (stage III and IV) a significant difference was only found
in group C for those with recurrence as compared to
Table I Mean Ta-4 level per stage and percentage above
2.7ngml 1
Ta-4 %
Stage ngml-' log Ta-4 s.d. Median Range >2.7ngml-
N* 1.88 0.26 0.42 2.2 0.8- 3.5 5
IB 2.34 0.17 2.21 3.7 0.2- 7.2 26.6
IIA 4.09 0.53 2.37 5.05 0.7- 9.4 66.6
IIB 16.0 0.89 18.24 28.2 1.5-54.9 68.7
III 8.6 0.74 9.6 17.5 1.6-33.4 75
IV 7.6 0.81 4.7 9.7 4.1-15.4 100
N* =value of Ta-4 in the serum of 50 healthy women.
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Figure 1 Ta-4 levels divided per stage.
patients without any sign of recurrence (see Table II). There
were 5 patients with a very high Ta-4 level (>35.0ngmV-1).
Four of them were in stage IIB and 3 of these 4 died within
18 months of the primary treatment.
Our results, showing an increase in mean Ta-4 level with
subsequent stages and higher values in patients with positive
lymph nodes and/or recurrence of the disease, resemble those
of Kato et al. (1982,1983). In serial Ta-4 determinations
after therapy they found a correlation between Ta-4 levels
and response to therapy (1979). Maruo et al. (1985) found a
decline of Ta-4 levels to normal within 72 h of radical
surgery and within 3 months of radiotherapy. Based on these
results they now give radiotherapy to those patients who do
not show a decrease of Ta-4 levels after surgery. Patients
who developed a recurrence showed a rise in Ta-4 levels in
Table II Mean log.Ta-4 per stage with or without
recurrence
Group No recurrence Recurrence P
mean mean
N log.Ta-4 N log.Ta-4
A(IB + IIA) 20 0.34 10 0.50 NS
B(IIB) 5 0.57 7 0.96 NS
C(III + IV) 6 0.55 7 1.03 0.02
Total 31 0.49 24 0.79 0.02
serum even before clinical signs of recurrence were detectable
(Kato et al., 1984).
A remarkable feature of our data is that the highest Ta-4
levels were found in group IIB, especially in those patients
suffering from a recurrence and who died within a few
months after therapy. Ta-4 may therefore indicate the degree
of activity of the tumour. The radioimmune assay method
used in this study was not sensitive enough to detect
sufficient amounts of Ta-4 in the early stages of cervical
cancer. However, Suehiro et al. (1986) recently published the
use of flow cytometric analysis of cervical smears with Ta-4
antiserum. With this combination they were able to detect
85% of squamous cervical carcinomas, with 20% false
positive results. Patients with pre-cancerous lesions had
abnormal histograms in 42% (CIN I and II) to 80% (CIN
III). The cellular localization of Ta-4 was investigated by
Ueda et al. (1986) by means of immunohistochemistry. Ta-4
could be detected in normal as well as in malignant cervical
tissue.
Further development of a monoclonal antibody against
squamous cell carcinoma of the cervix could provide an even
more specific tumour marker.
The conclusion from the present data and the above
mentioned literature is that Ta-4 could be a useful aid in the
detection and determination of the extent of disease in
patients with squamous cell cancer of the uterine cervix.
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